Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Retained Earnings: 2011-2025

Historic Retained Earnings for RedHill Biopharma (RDHL) over the last 11 years, with Jun 2025 value amounting to -$418.1 million.

  • RedHill Biopharma's Retained Earnings fell 1.97% to -$418.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$418.1 million, marking a year-over-year decrease of 1.97%. This contributed to the annual value of -$414.8 million for FY2024, which is 1.73% down from last year.
  • RedHill Biopharma's Retained Earnings amounted to -$418.1 million in Q2 2025, which was down 0.80% from -$414.8 million recorded in Q4 2024.
  • RedHill Biopharma's 5-year Retained Earnings high stood at -$302.3 million for Q1 2021, and its period low was -$433.9 million during Q4 2022.
  • Its 3-year average for Retained Earnings is -$402.7 million, with a median of -$408.9 million in 2023.
  • As far as peak fluctuations go, RedHill Biopharma's Retained Earnings crashed by 35.82% in 2021, and later increased by 6.02% in 2023.
  • RedHill Biopharma's Retained Earnings (Quarterly) stood at -$367.9 million in 2021, then declined by 17.94% to -$433.9 million in 2022, then increased by 6.02% to -$407.7 million in 2023, then decreased by 1.73% to -$414.8 million in 2024, then decreased by 1.97% to -$418.1 million in 2025.
  • Its Retained Earnings stands at -$418.1 million for Q2 2025, versus -$414.8 million for Q4 2024 and -$410.1 million for Q2 2024.